Showing 661 - 680 results of 1,171 for search 'antibody effect function', query time: 0.26s Refine Results
  1. 661

    THE THYROID GLAND STATUS IN PATIENTS WITH ANKYLOSING SPONDYLITIS DURING STANDARD THERAPY AND BIOLOGICAL THERAPY by G. R. Akhunova, F. V. Valeeva, I. G. Salikhov

    Published 2014-07-01
    “…The level of anti-thyroid antibodies, thyroid stimulating hormone (thyroid function) were correlated with active AS (index BASDAI), and the level of anti-thyroid antibodies were correlated with Creactive protein and erythrocyte sedimentation rate, the intensity of pain in the joints, number of swollen joints and inflamed enthesis.Therapy with non-steroidal anti-inflammatory drug is not provided significant effect on the structural and functional state of the thyroidgland, contributing to a downward trend in the level of antibodies to thyroid peroxidase. …”
    Get full text
    Article
  2. 662
  3. 663

    Bisecting GlcNAc enhances CD8+ T cell-mediated killing of breast cancer by suppressing PD-L1 expression and its binding to PD-1 by Xueting Ren, Jinpeng Wu, Jing Li, Zhen Zhai, Xiang Li, Feng Guan, Meng Wang, Xiaobin Ma, Zengqi Tan, Huafeng Kang, Shuai Lin

    Published 2025-08-01
    “…Additionally, forskolin, a bisecting GlcNAc agonist, was combined with anti-PD-L1 antibody to evaluate its antitumor effects in vivo. …”
    Get full text
    Article
  4. 664

    HEMOPHILIA: ADVANCES IN TREATMENTS by Nurgül Karakaya

    Published 2024-12-01
    “…PEG chains interfere with the recombinant factors binding to their clearance receptors, thereby prolonging circulating half-life.Emicizumab, a recombinant humanised bispecific IgG antibody, mimics the cofactor function of the missing FVIII in HA. …”
    Get full text
    Article
  5. 665
  6. 666

    Targeting Cancer with Paris’ Arrow: An Updated Perspective on Targeting Wnt Receptor Frizzled 7 by Kieran Hodson, Hector M. Arredondo, William E. Humphrey, Dustin J. Flanagan, Elizabeth Vincan, Karl Willert, Helen B. Pearson, Toby J. Phesse

    Published 2025-05-01
    “…Therapeutic strategies targeting FZD7 have shown promise, including FZD7-specific monoclonal antibody-drug conjugates (ADCs), human single-chain fragment variable (scFVs) antibodies, and nanoparticles. …”
    Get full text
    Article
  7. 667

    TRIM22 governs tumorigenesis and protects against endometrial cancer-associated cachexia by inhibiting inflammatory response and adipose thermogenic activity by Liping Zhang, Quanrong Li, Meiting Wu, Xiushan Feng, Weichao Dai, Peifang Chen, Dezhao Chen, Zhiqun Zheng, Xiaoyan Lin, Gang Wei

    Published 2025-04-01
    “…However, the detailed mechanism underlying EC-related cachexia and its harmful effects on EC progression and patient prognosis remains unclear. …”
    Get full text
    Article
  8. 668

    Disrupting Notch signaling related HES1 in myeloid cells reinvigorates antitumor T cell responses by Myung Sup Kim, Hyeokgu Kang, Jung-Hwan Baek, Moon-Gyu Cho, Eun Joo Chung, Seok-Jun Kim, Joon-Yong Chung, Kyung-Hee Chun

    Published 2024-12-01
    “…We further analyzed the TME composition, T cell infiltration and activation, and anti-tumor effects in these mice, both alone and in combination with PD-1 checkpoint blockade. …”
    Get full text
    Article
  9. 669

    Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy by Yu Bai, Tao Wu, Jun Lin, Shuwen Xu, Xian Zeng, Xuyao Zhang, Jiajun Fan, Dianwen Ju, Mengyang Li, Yanyang Nan, Xiaozhi Hu, Kaicheng Zhou, An Zhu, Zihan Dou, Zhonglian Cao, Xumeng Zhang, Yuanzhen Zhang, Xuebin Wang

    Published 2024-09-01
    “…Mechanistically, the superior antitumor activity of targeting IL-33 and PD-L1 originated from reducing immunosuppressive factors, such as Tregs and exhausted CD8+ T cells while increasing tumor-infiltrating cytotoxic T lymphocyte cells.Conclusions In this study, we demonstrated that IL-33/ST2 was involved in the immunosuppression mechanism of PD-L1 antibody therapy, and blockade by sST2-Fc or anti-PD-L1-sST2 could remodel the inflammatory TME and induce potent antitumor effect, highlighting the potential therapeutic strategies for the tumor treatment by simultaneously targeting IL-33 and PD-L1.…”
    Get full text
    Article
  10. 670

    Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen. by Gargi Das, Jakub Ptacek, Jana Campbell, Xintang Li, Barbora Havlinova, Satish Kumar Noonepalle, Alejandro Villagra, Cyril Barinka, Zora Novakova

    Published 2025-01-01
    “…Due to its tissue-specific expression and cell surface localization, PSMA shows superior potential for precise imaging and therapy of PCa. Antibody-based immunotherapy targeting PSMA offers the promise of selectively engaging the host immune system with minimal off-target effects. …”
    Get full text
    Article
  11. 671

    Characterization of pritumumab in murine models and primate safety study by Avani A. Mody, Rajesh Mukthavaram, Pengfei Jiang, Kishore Gangangari, Nagavarakishore Pillarsetty, Pranav R. Kesari, Vijay Padul, Sneha L. Kesari, Elnaz Rahbarlayegh, Mark C. Glassy, Santosh Kesari

    Published 2025-03-01
    “…A 29-day intravenous toxicology study in cynomolgus monkeys was carried out to analyze the safety and toxicity of pritumumab, and no toxic effects were observed. Overall, these data together suggest pritumumab is biologically active and animal models can be used to further understand the various functions of the antibody. …”
    Get full text
    Article
  12. 672

    Osteopontin derived from hypoxia-induced M2 macrophages promotes osteosarcoma progression through modulation of EGR3/ISG15 signaling and RIG-I expression by Chunyang Xing, Wei Hu, Liyuan Zhao

    Published 2025-08-01
    “…Methods Differentially expressed proteins in hypoxic macrophage supernatants were detected by antibody array. Cell functional experiments, siRNA-mediated gene silencing, and overexpression transfection were used to study osteopontin (OPN) and its supernatant effect. …”
    Get full text
    Article
  13. 673

    Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients by Yu Song, Qiao-Chen Geng, Wen-Jing An, Fu-Cheng Zhang, Ran Jiang, Rui-Sheng Zhao, Zhi-Jian Deng, Heng Li

    Published 2024-12-01
    “…In the clinical treatments of HER2-positive tumor patients, HER2 monoclonal antibodies, such as Herceptin, have shown well-defined therapeutic effects. …”
    Get full text
    Article
  14. 674

    The Severity of CVB3-Induced Myocarditis Can Be Improved by Blocking the Orchestration of NLRP3 and Th17 in Balb/c Mice by Jifei Chen, Fan Yang, Song Shi, Xuexiang Liu, Fengxian Qin, Xiaomou Wei, Yujie Huang, Wenwu Liang, Lin Miao

    Published 2021-01-01
    “…Background. The functional characteristics of NLRP3 in the pathogenesis of coxsackievirus B3- (CVB3-) induced viral myocarditis (VMC) have not been fully elucidated, and the targeted therapeutic effect of NLRP3 or its related pathway in VMC has not been reported. …”
    Get full text
    Article
  15. 675

    Detecting age-related changes in faecal vasoactive intestinal polypeptide using a 3D-printed electrochemical immunosensor by Khalil K. Hussain, Chloe Miller, Mark Yeoman, Bhavik Anil Patel

    Published 2025-10-01
    “…This novel VIP electrochemical immunosensor can be an effective tool for diagnosis or prognosis of various diseases given the diverse physiological function of VIP.…”
    Get full text
    Article
  16. 676

    Establishment of Epithelial Inflammatory Injury Model Using Intestinal Organoid Cultures by Chengfeng Xing, Guili Liang, Xin Yu, Anxing Zhang, Xiang Luo, Yu Liu, Zengli Tang, Bian Wu, Zhengji Song, Danfeng Lan

    Published 2023-01-01
    “…In this study, we successfully established an epithelial inflammatory injury model of intestinal organoids, which provides an effective in vitro model for studying the pathogenesis and treatment of IBD.…”
    Get full text
    Article
  17. 677
  18. 678

    An oncogene regulating chromatin favors response to immunotherapy<subtitle>Oncogene CHAF1A and immunotherapy outcomes</subtitle> by Leqian Ying, Zhangmin Hu, Yi Lu, Qing Tao, Fen Xiong, Yongqian Shu, Yufei Yang, Xuehan Qiao, Chen Peng, Yuchun Jiang, Miao Han, Min Xu, Xiaoqin Li, Deqiang Wang

    Published 2024-12-01
    “…In vivo, CHAF1A knockdown alone inhibited tumor growth but it impaired the effect of an anti-PD-1 antibody by increasing the relative tumor proliferation rate and decreasing the survival benefit, potentially through the activation of TGF-β signaling. …”
    Get full text
    Article
  19. 679

    Ginseng-Derived Exosomes Attenuate Immune Evasion in NSCLC via PD-L1 Modulation by Zhu LJ, Chen XQ, Lin QY, Feng JN, Yuan SF

    Published 2025-07-01
    “…In vivo, G-Exos treatment significantly inhibited tumor growth and, when combined with anti-PD-L1 monoclonal antibody, exhibited a synergistic effect characterized by greater tumor suppression and increased infiltration of cytotoxic CD8⁺ T cells in the tumor microenvironment.Conclusion: Ginseng-derived exosomes downregulate PD-L1 and enhance T-cell function, counteracting immune evasion in NSCLC. …”
    Get full text
    Article
  20. 680

    Prevalence of Autoimmune Thyroiditis and Other Autoimmune Diseases in Relation to Serum BAFF/APRIL Levels in Prolactinoma Patients by Özlem Kanburoğlu Meletli, Alev Altınova, Başak Bolayır, Resul Karakuş, Meriç Coşkun, Mehmet Muhittin Yalçın, Müjde Aktürk, İlhan Yetkin, Füsun Saadet Toruner

    Published 2024-01-01
    “…Autoimmune markers, including anti-nuclear antibody, rheumatoid factor immunoglobulin M (IgM) (RF-IgM), anti-double-stranded DNA (anti-dsDNA), anti-transglutaminase IgA (anti TG-IgA), and anti-Sjogren’s syndrome A (anti-ssA), serum BAFF, APRIL and vitamin B12 levels, thyroid function tests, anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin and thyroid Doppler ultrasound, were evaluated. …”
    Get full text
    Article